Clinicopathological Characteristics and Prognosis of Squamous Cell Carcinoma of the Breast: A Population-Based Analysis

Yiqun Han¹, Jiayu Wang¹, Zijing Wang¹, and Binghe Xu¹

Abstract

Background: To better understand the clinicopathological features and prognostic profiles of squamous cell carcinoma (SCC) of the breast.

Methods: Information on breast cancer was obtained from the Surveillance, Epidemiology, and End Results database (2004–2016). Comparative analyses were carried out to investigate the heterogeneity in the clinicopathological characteristics and survival outcomes between SCC and invasive ductal carcinoma (IDC), while propensity score matching was conducted to analyze the variations among baseline characteristics. Prognostic factors for SCC of the breast were successively identified using Cox regression analysis.

Results: A total of 382 SCC patients and 56,147 IDC patients were identified in this study. Comparatively, the SCC cohort exhibited a higher proportion of male individuals, poor differentiation, an advanced TNM stage, an increasing percentage of triple-negative (TN) subtype, an increasing rate of organ involvement, and less access to therapeutics. The aggressive profile was consistent in the TN subgroup, with a significantly higher proportion in SCC than in IDC (25.7% vs 6.8%). Prognosis of SCC was profoundly poorer than that of IDC (mOS, 78.6 months and 121.6 months, \( P < .0001 \); mBCSS 91.9 months vs 135.6 months, \( P < .0001 \)), of which the inferior tendency remained stable among disease stage and therapeutic options, while no difference was detected in the 2 subgroups with the TN subtype. The 2-year survival rate was 66.9% and the 5-year survival rate was 51.4%, with the risk factors being older age, bilateral disease, advanced TNM stage, bone and visceral involvement, surgical intervention, radiation treatment, and chemotherapy.

Conclusions: This study systematically analyzed the heterogeneous characteristics of SCC of the breast in comparison with IDC. Squamous cell breast cancer presented with increasing aggressive behavior and inferior prognosis. Prospective studies should focus on this subgroup and introduce individualized therapeutic protocols in clinical practice.

Keywords
squamous cell carcinoma, breast cancer, clinicopathological characteristics, prognosis, population-based study

Introduction
Squamous cell carcinoma (SCC) of the breast is a special histologic breast cancer, and its clinicopathological characteristics and survival outcomes are not well understood. Pure SCC of the breast, which accounts for more than 90% of malignant cells originating from squamous metaplasia, accounts for approximately 0.1% of all invasive breast cancer.¹ Due to its very low prevalence, a poor understanding exists regarding its clinical presentation, in association with the absence of less standard treatment of SCC of the breast.
Previous studies have assessed the clinical presentations of SCC of the breast. However, the majority of them focused on an insufficient sample size with a limited follow-up or discussed this subgroup of patients with the absence of comparators to fully understand the SCC-specific characteristics. The clinical features and prognostic profiles of SCC of the breast remain controversial, and given the undetermined consensus on this special subgroup, increasing evidence deserves thorough analysis to obtain a better understanding of the clinical outcomes in the SCC population. Herein, we conducted this study on a large-scale population, retrieved from the Surveillance, Epidemiology, and End Results (SEER) database, to comprehensively discuss the clinicopathological characteristics and prognosis of SCC of the breast, with the aim of curating an informative reference for practitioners in prospective practice.

Materials and Methods

Population

The information of patients diagnosed with breast cancer ranging from January 01, 2004 to December 31, 2016 was obtained from the SEER database (November 2018 submission), and individuals with the histologic type of invasive SCC were identified for the following analysis. Patients were excluded from the study in case of missing histologic confirmation.

Clinicopathological characteristics were extracted for the following data: age at diagnosis, sex, race, tumor grade, laterality, tumor size, node involvement, distant metastasis, subtype, estrogen receptor (ER) status, progesterone receptor (PgR) status, human epidermal growth factor receptor 2 (HER2) status, bone and visceral metastases, surgical intervention, radiation treatment, and chemotherapeutic delivery. This study was performed according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

Outcomes

Squamous cell breast cancer was considered a breast malignancy with the histologic type of SCC (ICD-O-3 8070-8078), while invasive ductal breast cancer was regarded as an invasive breast neoplasm with ductal carcinoma (ICD-O-3 8500). Overall survival (OS) was defined as the interval between the initial diagnosis of breast cancer and death due to any reason or the last follow-up. Breast cancer–specific survival (BCSS) refers to the period from the diagnosis of primary breast cancer to death caused by cancer progression. According to the SEER terminology, visceral metastases consist of lung, liver, and brain involvement. The American Joint Committee on Cancer 7th edition guidelines were adopted to define the TNM stage of breast cancer.

Statistical Analysis

Comparative analyses of demographics and clinicopathological features between invasive ductal carcinoma (IDC) and squamous cell breast cancer were performed using Pearson’s chi-squared and Fisher’s exact probability tests for qualitative data and the t-test or Wilcoxon rank test for quantitative data with and without normal distribution, respectively. Propensity score matching (PSM) was carried out to analyze objective distinctions between baseline characteristics of the two subgroups of breast cancer, including age at diagnosis, sex, race, tumor grade, laterality, TNM stage, molecular subtype, ER status, PR status, HER2 expression, and treatment options. The discrepancy in survival outcomes was explored using the Kaplan–Meier method with log-rank tests, in which the prognostic factors of squamous cell breast cancer were identified using univariate Cox regression analyses. All statistical analyses were two-sided, with a P value less than .05, considered as statistically significant, and performed using IBM SPSS Statistics (version 26.0, Armonk, NY, IBM Corp) and R software (version 3.6.4).

Results

Clinicopathological Characteristics

In this study, 382 patients with SCC of the breast were eligible for inclusion. The differences in the baseline characteristics between the two cohorts are presented in Table A.1. The median age of patients with IDC and SCC was 60.88 and 66.51 years, respectively. In comparisons with IDC, patients with squamous cell breast cancer exhibited a higher proportion of male individual (2.6% vs 1.8%, P < .0001), a higher tumor grade (III-IV, 50.0% vs 30.6%, P < .0001), an enlarged tumor size (>5 cm, 19.9% vs 5.2%, P < .0001), a higher rate of node involvement (N0/1 mi, 34.6% vs 41.9%, P = .013), a higher incidence of initial distant metastasis (M1, 6.0% vs 2.9%, P < .0001), an increasing percentage of hormone receptor (HR)/HER2- (TN) subtype (25.7% vs 6.8%, P < .0001), as well as increasing incidences of metastases in both bone (2.1% vs 1.8%, P = .016) and viscera (lung 3.4% vs .9%, P < .0001; liver 1.6% vs .7%, P = .002; brain .5% vs .2%, P = .007). Regarding therapeutic options, breast cancer patients with SCC tended to be less accessible to surgical (82.2% vs 92.0%, P < .0001) and radiation (31.9% vs 48.1%, P < .0001) interventions, while no statistical divergence was detected in the performance rate of chemotherapy between the two groups. Regarding the patients with the TN subtype, it was denoted that a consistent pattern could be detected in % difference between the two cohorts, including an older age at diagnosis (67.38 years vs 58.63 years, P < .0001), a higher percentage of male patients (3.1% vs 1.9%, P < .0001), increased tumor size (>5 cm, 38.8% vs 13.9%, P < .0001), a higher incidence of distant involvement (M1, 13.3% vs 5.6%, P = .004), a higher rate of lung metastasis (7.1% vs 2.2%, P = .005), and a
declining percentage of surgical performance (82.7% vs 90.4%, \( P = .009 \)), in which the corresponding discrepancies tended to be more apparent than those in the entire population. No statistical significance was explored in the majority of organ-specific metastases, including bone, liver, and brain, and radiotherapy, while the chemotherapeutic application was significantly decreased in the SCC subgroup patients (Supplementary Table S1).

**Prognosis**

Substantial differences were detected in the prognosis profiles of patients in the two subgroups. The overall prognosis of the SCC cohort was significantly lower than that of IDC patients, with the median OS (mOS) of 78.6 months and 121.6 months (\( P < .0001 \)), respectively, and the difference was similar to that of the median BCSS (mBCSS) between the two groups (91.9 months vs 135.6 months, \( P < .0001 \)) (Figure A1A and 1B). This kind of prognostic discrepancy remained consistent between the SCC and IDC cohorts with the TN subtype (mOS, 57.9 months vs 65.9 months, \( P = .007 \); mBCSS, 59.2 months vs 69.3 months, \( P = .002 \)) (Supplementary Figure S1A and 1B). Furthermore, SCC breast cancer exhibited a comparatively decreased OS at both early (mOS, 57.5 months vs 125.8 months, \( P < .0001 \); mBCSS, 63.1 months vs 141.2 months, \( P < .0001 \)) and advanced (mOS, 17.9 months vs 52.4 months, \( P < .0001 \); mBCSS, 16.1 months vs 56.5 months, \( P < .0001 \)) stage in the cancer course (Supplementary Figure S2A-2D). Regarding therapeutic options, patients undergoing surgery (mOS, 102.5 months vs 126.3 months, \( P < .0001 \); mBCSS, 102.7 months vs 140.1 months, \( P < .0001 \)), radiotherapy (mOS, 110.7 months vs 132.5 months, \( P < .0001 \); mBCSS, 119.9 months vs 142.3 months, \( P < .0001 \)), and chemotherapy (mOS, 103.0 months vs 129.3 months, \( P < .0001 \); mBCSS, 107.1 months vs 135.6 months, \( P < .0001 \)) tended to present an inferior prognosis in the SCC cohort (Supplementary Figure S3-S5).

To eliminate the uneven distributions in baseline characteristics, the PSM analysis in a 1:5 (SCC/IDC) was performed to investigate the heterogeneity in survival outcomes between the two cohorts, of which the results signified that the inferior tendency of both OS and BCSS remained stable in breast cancer patients with SCC (mOS, 78.9 months vs 97.1 months, \( P < .0001 \); mBCSS, 92.5 months vs 115.7 months, \( P < .0001 \)) (Figure A2A and 2B). In the TN subgroups, however, no statistical significance was observed in the survival between patients from the SCC and IDC cohorts (mOS, 58.7 months vs 56.6 months, \( P = .866 \); mBCSS, 60.1 months vs 63.0 months, \( P = .356 \)) (Supplementary Figure S6A and 6B).

In the entire SCC cohort, the 2-year survival rate was 66.9%, and the 5-year survival rate was 51.4%. Regarding the TNM stage, there were 9.7% (37/382) of stage I, 20.4% (78/382) of stage II, 11.8% (45/382) of stage III, and 6.0% (23/382) of stage IV at initial diagnosis, of which the mOS were 62.8 months, 65.8 months, 37.3 months, and 17.9 months, and the mBCSS were 73.1 months, 70.5 months, 43.9 months, and 16.1 months, respectively (Supplementary Figure S7A and 7B). Comparative analysis of survival outcomes revealed that there was no statistical significance between the OS of stage I and stage II, which was greatly improved compared to that of disease at the advanced stage, including stage III and stage IV (Supplementary Table S2). A consistent tendency was detected in the BCSS of SCC of patients with breast cancer (Supplementary Table S3). The survival outcomes of patients with heterogeneous characteristics are presented in Supplementary Tables S4 and S5. The prognostic factors for OS were successively identified using Cox regression analysis, which included age (\( P < .0001 \)), bilaterality (\( P < .0001 \)), advanced TNM stage (\( P < .0001 \)), bone involvement (\( P < .0001 \)), lung involvement (\( P < .0001 \)), liver involvement (\( P < .0001 \)), brain involvement (\( P < .0001 \)), surgery, radiotherapy (\( P < .0001 \)), and chemotherapy (\( P < .0001 \)), which are similar with those for BCSS (Table A2).

**Discussion**

Although various evidence has been proposed from previous studies on the clinical features of SCC of the breast, it was rather insufficient, and this subgroup of breast malignancy deserves to be elaborated in depth. In this study, we systematically discussed the heterogeneity in clinicopathological features and survival outcomes of SCC of breast compared to IDC, taking full consideration of diverse clinical variables and focusing on the TN subtype with an illustration of the specific variability of this subgroup, which could provide a promising reference for the current practice.

First, we investigated the heterogeneous presentations between the SCC and IDC cohorts. It has been suggested that the disease characteristics of SCC tend to be more aggressive than those of IDC with the presentation of an advanced TNM stage and organic metastases, which was consistent with the findings of previous studies.\(^3,9\) Comparative analysis of survival profiles demonstrated that the prognosis of squamous cell breast cancer was significantly worse than that of IDC, which was independent of the disease stage and therapeutic applications. This sort of inferior prognosis remained constant after calibrating the uneven distributions among baseline characteristics with the performance of PSM analysis. From this perspective, we provided a landscape of intrinsic heterogeneity in the two subgroups and revealed the poorer survival associated with the aggressive behavior existing in this special histologic type.

Considering the overwhelming proportion of the TN subtype in the SCC cohort (25.7% vs 6.8%), we performed a systematic analysis and investigated the potential features existing in this subgroup. Aggressive disease features of TN subgroup patients were revealed compared to those with IDC, while the patients with SCC of the breast were less accessible to therapeutics, especially for systemic treatment, and the prognosis was significantly worse than that of the IDC cohort.
This kind of prognostic discrepancy could be the result of insufficient therapeutic application, which was further confirmed by the undifferentiated survival between the SCC and IDC cohorts after PSM analysis. Although some studies have noted that the positive rate of hormone receptors tended to be lower in SCC, few analyses have been performed based on this subtype. Of note, this study was one of the few studies focused on the TN subgroup and revealed the potential underlying causes of prognostic discrepancy between the two subgroups of patients. Given the fact that there are limited options for TN subtype breast cancer except for systemic therapies, physicians should take full consideration of the SCC of the breast while introducing multi-disciplinary therapeutic protocols with sufficient intensity.

In this study, the survival probability was estimated at a 5-year OS rate of 51.4%. Similarly, based on the SCC population, Yadav et al. reported the 5-year survival rate of SCC of the breast as 52.9%, in which the divergence might be the result of the different period for population enrollment (1998–2013 vs 2004–2016). However, the 5-year survival probability significantly varied among previous studies with a range of 34.5–84.0%, which could be attributed to the discrepancies in sample size and study design. Risk factors for SCC were identified, including older age, advanced disease TNM stage, and organ involvement, which were similar to the data reported by prior studies focusing on breast cancer with other histologic types.

Our study highlighted the substantial heterogeneity in the clinical features of breast cancer with squamous differentiation. Currently, clinical trials designed for breast cancer tend to ignore the histological classifications, which probably results in bias regarding clinical significance. Under these circumstances, histological features should be adopted to study protocols for unbiased design and promising survival benefits. In addition, given the profound heterogeneity between the two subgroups, whether therapeutic patterns were supposed to be introduced following the histologic type remained undetermined. This study focused on the differences between SCC and IDC, which was the most frequent subtype in breast cancer, and illuminated that treatment options should be applied in accordance with individualized factors. However, this study has several limitations. First, there is a proportion of missing data among the clinical variables, which might result in misestimation and potentially weaken the power of our findings. Second, some information regarding disease characteristics and therapies are not recorded in the SEER database, such as the KI-67 index and lymphovascular invasion, in addition to the implementation of endocrine and targeted therapies; therefore, we cannot elucidate the associations between these factors and clinical presentations. Last, given the fact that the specific coding based on ICD-O-3 are not given in the SEER database, thus the “pure” SCC of which the proportion of malignant cells differentiated as squamous type is usually more than 90%, could not be fully identified in this study.

**Conclusions**

In conclusion, this study revealed profound heterogeneity in the clinicopathological characteristics and prognosis of SCC of the breast in comparison with IDC. Squamous cell breast cancer presented with increasing aggressive behavior and inferior prognosis as well as a notable proportion of the TN subtype. Prospective studies should focus on this subgroup and introduce individualized therapeutic protocols in clinical practice.

**Author’s Note**

The present study was performed in compliance with the Declaration of Helsinki. Permission was obtained to access the SEER database.

**Declaration of Competing Interests**

The authors declared no potential conflicts of interests with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Yiqun Han  \url{https://orcid.org/0000-0001-5338-3058}

**Supplemental Material**

Supplemental material for this article is available online.

**References**

1. Henessy BT, Krishnamurthy S, Giordano S, et al. Squamous cell carcinoma of the breast. J Clin Oncol. 2005;23(31):7827-7835. doi:10.1200/jco.2004.00.9589
2. Zhang X-M, Zhang B, Zang F, Zhao L, Yuan Z, Wang P. Clinical features and treatment of squamous cell carcinoma of the breast. Onco Targets Ther. 2016;9:3181-3185. doi:10.2147/ott.S95128
3. Yadav S, Yadav D, Zakalik D. Squamous cell carcinoma of the breast in the United States: incidence, demographics, tumor characteristics, and survival. Breast Canc Res Treat. 2017;164(1):201-208. doi:10.1007/s10549-017-4251-3
4. Liu J, Yu Y, Sun J-Y, et al. Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Canc Res Treat. 2015;149(1):133-140. doi:10.1007/s10549-014-3224-z
5. Menes T, Schachter J, Morgenstern S, Fenig E, Lurie H, Gutman H. Primary squamous cell carcinoma (SqCC) of the breast. Am J Clin Oncol. 2003;26(6):571-573. doi:10.1097/01.coc.0000045809.85995.3B
6. Pandey A, Joshi K, Moussouris H, Joseph G. Case reports on metaplastic squamous cell carcinoma of the breast and treatment dilemma. Case Rep Oncol Med. 2019;2019:1-6. doi:10.1155/2019/4307281
7. Cardoso F, Leal C, Meira A, et al. Squamous cell carcinoma of the breast. *Breast*. 2000;9(6):315-319. doi:10.1054/brst.1999.0145
8. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. 2007;370(9596):1453-1457. doi:10.1016/s0140-6736(07)61602-x
9. Zhu L, Chen K. Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis. *BMC Canc*. 2019;19(1). doi:10.1186/s12885-018-5212-x
10. Mo H, Xu B. Progress in systemic therapy for triple-negative breast cancer. *Front Med*. 2021;15(1):1-10. doi:10.1007/s11684-020-0741-5
11. Nayak A, Wu Y, Gilcrease MZ. Primary squamous cell carcinoma of the breast. *Am J Surg Pathol*. 2013;37(6):867-873. doi:10.1097/PAS.0b013e3182877569
12. Benoist P, Mureau A, Joueidi Y, et al. Management and prognosis of pure primary squamous cell carcinoma of the breast. *J Gynecol Obstet Hum Reprod*. 2018;47(7):275-280. doi:10.1016/j.jogoh.2018.06.007
13. Grenier J, Soria JC, Mathieu MC, et al. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. *Anticancer Res*. 2007;27:547-555.
14. Brandt J, Garne J, Tengrup I, Manjer J. Age at diagnosis in relation to survival following breast cancer: a cohort study. *World J Surg Oncol*. 2015;13:33. doi:10.1186/s12957-014-0429-x
15. Han Y, Wang J, Xu B. Clinicopathological characteristics and prognosis of breast cancer with special histological types: a surveillance, epidemiology, and end results database analysis. *Breast*. 2020;54:114-120. doi:10.1016/j.breast.2020.09.006
16. Behranwala KA, Nasiri N, Abdullah N, Trott PA, Gui GPH. Squamous cell carcinoma of the breast: clinicopathologic implications and outcome. *Eur J Surg Oncol*. 2003;29(4):386-389. doi:10.1053/ejso.2002.1422

Appendices

Table A1. Baseline characteristics of IDC and SCC breast cancer.

| Characteristic          | IDC (N = 561477) | SCC (N = 382) | P value |
|------------------------|-----------------|--------------|---------|
| Age, years             | 60.88           | 66.51        | <.0001  |
| Age group, years       |                 |              |         |
| <40                    | 30722           | 15           | <.0001  |
| 40–54                  | 161786          | 79           | 0.001   |
| 55–70                  | 225706          | 125          | 0.012   |
| >70                    | 143263          | 163          | 0.008   |
| Sex                    |                 |              |         |
| Female                 | 556731          | 372          | 0.001   |
| Male                   | 4746            | 10           | 0.017   |
| Race                   |                 |              | <.0001  |
| White                  | 444531          | 305          | 0.001   |
| Black                  | 62754           | 56           | 0.001   |
| Others                 | 54192           | 21           | 0.001   |
| Grade                  |                 |              | <.0001  |
| Grade 1                | 106919          | 34           | 0.001   |
| Grade 2                | 225032          | 93           | 0.001   |
| Grade 3                | 201856          | 182          | 0.001   |
| Grade 4                | 3585            | 9            | 0.001   |
| Unknown                | 24085           | 64           | 0.001   |
| Laterality             |                 |              | <.0001  |
| Left                   | 284385          | 198          | 0.001   |
| Right                  | 276384          | 180          | 0.001   |
| Others                 | 708             | 4            | 0.001   |
| T                      |                 |              | <.0001  |
| T0/T1                  | 196421          | 41           | 0.001   |
| T2                     | 94120           | 63           | 0.001   |
| T3                     | 15999           | 40           | 0.001   |
| T4                     | 13458           | 36           | 0.001   |
| TX/unknown             | 241479          | 202          | 0.001   |

(continued)
Table A1. (continued)

| Characteristic                  | IDC (N = 561477) | SCC (N = 382) | P value |
|--------------------------------|------------------|--------------|---------|
|                                | No. | Percent, % | No. | Percent, % |        |
| N                              |     |            |     |            | .013   |
| N0/N1mi                        | 235209 | 41.9 | 132 | 34.6 |        |
| N1                             | 62664  | 11.2 | 43  | 11.3 |        |
| N2                             | 16175  | 2.9  | 15  | 3.9  |        |
| N3                             | 9303   | 1.7  | 3   | 0.8  |        |
| NX/unknown                     | 238126 | 42.4 | 189 | 49.5 |        |
| M                              |     |            |     |            | <.0001 |
| M0                             | 313305 | 55.8 | 176 | 46.1 |        |
| M1                             | 16127  | 2.9  | 23  | 6.0  |        |
| Unknown                        | 232045 | 41.3 | 183 | 47.9 |        |
| Subtype                        |     |            |     |            | <.0001 |
| HR+/HER2−                      | 211987 | 37.8 | 41  | 10.7 |        |
| HR+/HER2+                      | 36556  | 6.5  | 4   | 1.0  |        |
| HR−/HER2+                      | 16186  | 2.9  | 7   | 1.8  |        |
| HR−/HER2−                      | 38061  | 6.8  | 98  | 25.7 |        |
| Unknown                        | 258687 | 46.1 | 232 | 60.7 |        |
| ER                             |     |            |     |            | <.0001 |
| Positive                       | 425455 | 75.8 | 63  | 16.5 |        |
| Negative                       | 113685 | 20.2 | 230 | 60.2 |        |
| Borderline/unknown             | 22337  | 4.0  | 89  | 23.3 |        |
| PgR                            |     |            |     |            | <.0001 |
| Positive                       | 364785 | 65.0 | 37  | 9.7  |        |
| Negative                       | 170520 | 30.4 | 256 | 67.0 |        |
| Borderline/unknown             | 26172  | 4.7  | 89  | 23.3 |        |
| HER2                           |     |            |     |            | <.0001 |
| Positive                       | 52860  | 9.4  | 11  | 2.9  |        |
| Negative                       | 250390 | 44.6 | 139 | 36.4 |        |
| Borderline/unknown             | 258227 | 46.0 | 232 | 60.7 |        |
| Bone involvement               |     |            |     |            | .016   |
| Yes                            | 10003  | 1.8  | 8   | 2.1  |        |
| No                             | 310030 | 55.2 | 183 | 47.9 |        |
| Unknown                        | 241444 | 43.0 | 191 | 50.0 |        |
| Lung involvement               |     |            |     |            | <.0001 |
| Yes                            | 5262   | 0.9  | 13  | 3.4  |        |
| No                             | 314537 | 56.0 | 177 | 46.3 |        |
| Unknown                        | 241678 | 43.0 | 192 | 50.3 |        |
| Liver involvement              |     |            |     |            | .002   |
| Yes                            | 4140   | 0.7  | 6   | 1.6  |        |
| No                             | 315780 | 56.2 | 185 | 48.4 |        |
| Unknown                        | 241557 | 43.0 | 191 | 50.0 |        |
| Brain involvement              |     |            |     |            | .007   |
| Yes                            | 1134   | 0.2  | 2   | 0.5  |        |
| No                             | 318683 | 56.8 | 189 | 49.5 |        |
| Unknown                        | 241660 | 43.0 | 191 | 50.0 |        |
| Surgery                        |     |            |     |            | <.0001 |
| No/unknown                     | 45193  | 8.0  | 68  | 17.8 |        |
| Yes                            | 516284 | 92.0 | 314 | 82.2 |        |
| Radiotherapy                   |     |            |     |            | <.0001 |
| No/unknown                     | 291142 | 51.9 | 260 | 68.1 |        |
| Yes                            | 270335 | 48.1 | 122 | 31.9 |        |
| Chemotherapy                   |     |            |     |            | .518   |
| No/unknown                     | 326641 | 58.2 | 216 | 56.5 |        |
| Yes                            | 234836 | 41.8 | 166 | 43.5 |        |

Abbreviations: SCC, squamous cell carcinoma; IDC, invasive ductal carcinoma; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PgR, progesterone receptor.
Figure A1. OS (A) and BCSS (B) of IDC and SCC cohorts. Abbreviations: SCC, squamous cell carcinoma; IDC, invasive ductal carcinoma; OS, overall survival; BCSS, breast cancer–specific survival.

Figure A2. OS (A) and BCSS (B) of IDC and SCC cohorts after a 1:5 PSM analysis. Abbreviations: SCC, squamous cell carcinoma; IDC, invasive ductal carcinoma; OS, overall survival; BCSS, breast cancer–specific survival.
| Characteristic     | OS                      | P value | BCSS                      | P value |
|-------------------|-------------------------|---------|---------------------------|---------|
|                   | Hazard ratio (95%CI)    |         | Hazard ratio (95%CI)      |         |
| Age group, years  |                         | <.0001  |                          | .002    |
| <40               | Reference               |         | Reference                 |         |
| 40–54             | 1.89 (0.57–6.19)        | .295    | 1.72 (0.52–5.72)          | .375    |
| 55–70             | 1.82 (0.57–5.86)        | .316    | 1.57 (0.48–5.19)          | .459    |
| >70               | 3.97 (1.26–12.51)       | .019    | 3.37 (1.05–10.81)         | .041    |
| Sex               |                         | .737    |                          | .839    |
| Male              | Reference               |         | Reference                 |         |
| Female            | 1.15 (0.51–2.59)        | .737    | 1.15 (0.28–4.69)          | .839    |
| Race              |                         | .328    |                          | .260    |
| White             | Reference               |         | Reference                 |         |
| Black             | 1.23 (0.83–1.81)        | .298    | 1.49 (0.93–2.39)          | .101    |
| Others            | 0.69 (0.32–1.46)        | .329    | 1.07 (0.49–2.32)          | .871    |
| Laterality        |                         | <.0001  |                          | .036    |
| Left              | Reference               |         | Reference                 |         |
| Right             | 0.94 (0.70–1.26)        | .680    | 0.88 (0.59–1.31)          | .528    |
| Others            | 7.22 (2.62–19.89)       | <.0001  | 5.71 (1.38–23.599)        | .016    |
| Grade             |                         | .065    |                          | .596    |
| Grade 1           | Reference               |         | Reference                 |         |
| Grade 2           | 1.08 (0.60–1.95)        | .790    | 1.21 (0.49–2.99)          | .681    |
| Grade 3           | 1.15 (0.66–1.98)        | .627    | 1.52 (0.65–3.53)          | .336    |
| Grade 4/unknown   | 0.52 (0.15–1.79)        | .301    | 1.62 (0.66–3.95)          | .293    |
| T                 |                         | .01     |                          | .002    |
| T0/T1             | Reference               |         | Reference                 |         |
| T2                | 2.12 (0.33–2.77)        | .650    | 3.18 (0.29–4.74)          | .810    |
| T3                | 2.21 (0.97–5.05)        | .060    | 3.03 (0.83–10.99)         | .093    |
| T4                | 4.07 (1.85–9.95)        | <.0001  | 6.26 (1.79–21.81)         | .004    |
| TX/unknown        | 2.36 (1.19–4.66)        | .013    | 3.85 (1.21–12.25)         | .022    |
| N                 |                         | .04     |                          | .008    |
| N0/N1mi           | Reference               |         | Reference                 |         |
| N1                | 1.79 (1.02–3.16)        | .043    | 2.07 (0.99–4.29)          | .051    |
| N2                | 3.55 (1.76–7.17)        | <.0001  | 4.11 (1.71–9.87)          | .002    |
| N3                | 3.29 (0.79–13.67)       | .102    | 4.38 (1.02–18.89)         | .048    |
| NX/unknown        | 1.64 (1.12–2.40)        | .011    | 2.16 (1.27–3.65)          | .004    |
| M                 |                         | <.0001  |                          | <.0001  |
| M0                | Reference               |         | Reference                 |         |
| M1                | 4.77 (2.77–8.20)        | <.0001  | 6.59 (3.44–12.61)         | <.0001  |
| Unknown           | 1.47 (1.04–2.06)        | .028    | 1.91 (1.21–3.02)          | .006    |
| TNM               | <.0001                  |         | <.0001                    |         |
| I                 | Reference               |         | Reference                 |         |
| II                | 1.09 (0.45–2.69)        | .843    | 2.98 (0.37–24.21)         | .307    |
| III               | 3.48 (1.48–8.20)        | .004    | 10.31 (1.35–78.82)        | .025    |
| IV                | 8.50 (3.54–20.44)       | <.0001  | 34.89 (4.58–265.87)       | .001    |
| Unknown           | 2.66 (1.24–5.71)        | .012    | 10.19 (1.41–73.44)        | .021    |
| Subtype           |                         | .296    |                          | .499    |
| HR+/HER2+         | Reference               |         | Reference                 |         |
| HR+/HER2+         | 0.39 (0.05–2.92)        | .360    | 0.95 (0.12–7.61)          | .962    |
| HR/-HER2+         | 1.25 (0.37–4.23)        | .725    | 2.47 (0.52–11.65)         | .254    |
| HR/-HER2–         | 0.61 (0.34–1.11)        | .107    | 1.00 (0.44–2.31)          | .992    |
| Unknown           | 0.91 (0.55–1.49)        | .695    | 1.44 (0.69–2.99)          | .331    |
\begin{table}[h]
\centering
\begin{tabular}{llllll}
\hline
Characteristic & & OS & & & BCSS \\
& & Hazard ratio (95%CI) & \(P\) value & & Hazard ratio (95%CI) & \(P\) value \\
\hline
Bone involvement & & \multicolumn{2}{c}{<.0001} & & \multicolumn{2}{c}{<.0001} \\
No & Reference & & & & Reference & \\
Yes & 6.99 (3.32–14.74) & .021 & & 6.69 (2.79–16.07) & <.0001 \\
Unknown & 1.47 (1.06–2.05) & <.0001 & & 1.73 (1.13–2.66) & .012 \\
Lung involvement & & \multicolumn{2}{c}{<.0001} & & \multicolumn{2}{c}{<.0001} \\
No & Reference & & & & Reference & \\
Yes & 6.84 (3.53–13.23) & <.0001 & & 10.67 (4.63–24.56) & <.0001 \\
Unknown & 1.57 (1.12–2.20) & .009 & & 1.86 (1.20–2.89) & .005 \\
Liver involvement & & \multicolumn{2}{c}{<.0001} & & \multicolumn{2}{c}{<.0001} \\
No & Reference & & & & Reference & \\
Yes & 6.51 (2.59–16.36) & <.0001 & & 14.65 (5.09–42.12) & <.0001 \\
Unknown & 1.41 (1.02–1.94) & .039 & & 1.66 (1.09–2.53) & .019 \\
Brain involvement & & \multicolumn{2}{c}{<.0001} & & \multicolumn{2}{c}{<.0001} \\
No & Reference & & & & Reference & \\
Yes & 24.33 (5.69–104.01) & <.0001 & & 46.88 (5.69–386.38) & <.0001 \\
Unknown & 1.36 (0.99–1.86) & .062 & & 1.54 (1.02–2.32) & .039 \\
Surgery & & \multicolumn{2}{c}{<.0001} & & \multicolumn{2}{c}{<.0001} \\
No/unknown & Reference & & & & Reference & \\
Yes & 0.30 (0.22–0.42) & <.0001 & & 0.27 (0.17–0.41) & <.0001 \\
Radiotherapy & & \multicolumn{2}{c}{<.0001} & & \multicolumn{2}{c}{<.0001} \\
No/unknown & Reference & & & & Reference & \\
Yes & 0.53 (0.37–0.74) & <.0001 & & 0.52 (0.34–0.82) & .004 \\
Chemotherapy & & \multicolumn{2}{c}{<.0001} & & \multicolumn{2}{c}{<.0001} \\
No/unknown & Reference & & & & Reference & \\
Yes & 0.57 (0.42–0.77) & <.0001 & & 0.73 (0.49–1.08) & .112 \\
\hline
\end{tabular}
\caption{continued}
\end{table}

Abbreviations: SCC, squamous cell carcinoma; OS, overall survival; BCSS, breast cancer–specific survival; IDC, invasive ductal carcinoma; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PgR, progesterone receptor.